×

Cellular Biomedicine Group to Provide Business and Clinical Updates at Jefferies 2015 Global Healthcare Conference

SHANGHAI, China and PALO ALTO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that Tony (Bizuo) Liu, Chief Financial Officer of the Company, will be presenting at the Jefferies 2015 Global Healthcare Conference in New York on June 1, at 4:30PM EDT.

Tony will be providing an update on CBMG's business strategy, key corporate developments and an update on recent clinical trials including clinical data from its Chimeric Antigen Receptor (CAR-T) CD30-positive Hodgkin's lymphoma immuno-oncology Phase I trial, recently presented at the 10th Annual World Stem Cells & Regenerative Medicine Congress in London, UK on May 21, 2015.

Highlights on CD30:

  • Phase I, open-label trial (NCT02259556)
  • All trial participants presenting with stage III and IV Hodgkin's lymphoma, relapsed and refractory to other standard-of-care therapies
  • Conditioning regimen before cells infusion was applied
  • Subsequent allogeneic HSCT (hematopoietic stem cell transplant) was not applied
  • 2 out of 7 patients achieved partial response (PR)
  • 3 out of 7 patients obtained stable disease (SD)
  • Overall disease control rate of 71.4% (5/7)
  • Objective response rate of 28.6% (2/7)
  • No delayed and severe adverse events occurred post the CBM-C30.1 cells infusion

The presentation will be webcast and may be accessed with the following link and on CBMG's website under the Investor Relations section: http://wsw.com/webcast/jeff88/cbmg

The presentation will be archived for 90 days on the website after the event.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 vivian.chen@grayling.com

Source:Cellular Biomedicine Group Inc.